Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 2/20 | 0.67 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.58 |
| ▸ | RARB | P10826 | 6/20 | 0.54 |
| ▸ | THRA | P10827 | 3/20 | 0.53 |
| ▸ | THRB | P10828 | 3/20 | 0.53 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | RARA | P10276 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24534632 | 0.95 | PLK1 (0.60) | PLK1TRPV1RARBTHRATHRB | |
| SCHEMBL24534900 | 0.94 | HAO1 (0.59) | PLK1TRPV1RARBTHRATHRB | |
| SCHEMBL24534776 | 0.91 | PLK1 (0.65) | PLK1TRPV1THRBALDH1A1KDM4E | |
| SCHEMBL22505170 | 0.87 | PLK1 (0.65) | PLK1TRPV1RARBTHRATHRB | |
| SCHEMBL28459349 | 0.82 | TRPV1 (0.63) | PLK1TRPV1RARBTHRATHRB | |
| SCHEMBL24534531 | 0.81 | PLK1 (0.59) | PLK1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL6958590 | 0.80 | PLK1 (1.00) | PLK1TRPV1RARBTHRATHRB | |
| SCHEMBL6958582 | 0.79 | PLK1 (0.72) | PLK1TRPV1RARBTHRATHRB | |
| SCHEMBL28645496 | 0.79 | RARB (0.62) | PLK1TRPV1RARBTHRATHRB | |
| SCHEMBL28465310 | 0.78 | TRPV1 (0.58) | PLK1TRPV1RARBTHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220193041-A1 | NOVEL COMPOUND AND METHOD FOR PREVENTING OR TREATING OF RESPIRATORY DISEASES COMPRISING THE SAME AS AN ACTIVE INGREDIENT | Yonsei University, University - Industry Foundation (UIF) (KR) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193041-A1 | NOVEL COMPOUND AND METHOD FOR PREVENTING OR TREATING OF RESPIRATORY DISEASES COMPRISING THE SAME AS AN ACTIVE INGREDIENT | EPX, CFTR, MPO | PLK1 3407/4885TRPV1 213/4885RARB 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.